THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that the results of the initial Phase I/II clinical trial of Proellex® which was conducted in Europe are to be published in US Obstetrics and Gynecology Review in early August. In this study, women with fibroids were treated with Lucrin® (also known as Lupron®), one of three doses of Proellex, or placebo. Decreases in fibroid size were detected by ultrasound and there was a notable reduction in vaginal bleeding. The drug appeared in the blood within an hour of oral treatment and the two highest doses were roughly comparable in terms of blood levels although the highest level used (50mg per day) appeared to exert its effects on fibroid size within one month. Few adverse events could be attributed to Proellex. Pre-prints will be available in limited numbers on July 24th (at Repros’ Analyst Day Meeting see www.reprosrx.com) and will be widely available after August 1st from the company and elsewhere as Wiehle et al. 2008 US Obstet Gynecol Rev 3(1), 17-20.
